CASMED Places 1,000th FORE-SIGHT(R) Cerebral Oximeter

CAS Medical Systems Logo

BRANFORD, Conn., March 20, 2014 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) (CASMED), a leader in medical devices for non-invasive patient monitoring, today announced that the worldwide cumulative net shipment total of FORE-SIGHT Cerebral Oximeters reached 1,000 as of last week. This total includes monitors installed at nine of the top 20 adult cardiac surgery centers and three of the top ten pediatric centers in the U.S. The Company had previously disclosed a net cumulative total of 935 units as of December 31, 2013.

"Reaching this significant milestone is a sign of the continued strong market acceptance of the FORE-SIGHT ELITE™ monitor, which was introduced in September," said Tom Patton, CASMED's President and CEO. "Most importantly, cumulative sales of our disposable oximetry sensors have surpassed 300,000, meaning more than 150,000 adult, child, and newborn patients have benefited from the use of FORE-SIGHT technology. Improving patient care is one of CASMED's core values, and it is rewarding to know that with FORE-SIGHT oximetry we have enabled clinicians around the world to provide better outcomes for so many people.

"In response to the growing interest in cerebral oximetry and the demand for our products, we recently added four direct sales representatives in the U.S. to handle territories where we had been under-represented by independent distributors, bringing our U.S. distribution to nine direct reps plus three manufacturer's rep organizations."

About CASMED® – Monitoring What's Vital

CASMED is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximetry technology provides highly accurate, non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation. Direct monitoring of tissue oxygenation provides a superior and powerful tool to alert clinicians to otherwise unrecognized and dangerously low levels of oxygenation of the brain and other tissues, thereby allowing them to intervene appropriately in the care of their patients. In addition to FORE-SIGHT Oximeters and accessories, the Company provides a line of bedside patient vital signs monitoring products, proprietary non-invasive blood pressure monitoring solutions for OEM use, neonatal intensive care supplies, and service. CASMED products are designed to provide unique monitoring solutions that are vital to patient care. For further information regarding CASMED, visit the Company's website at www.casmed.com.

Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the impact of any product liability or other adverse litigation, working capital and availability of capital, commercialization and technological difficulties, the impact of actions and events involving key customers, vendors, lenders, competitors, and other risks detailed in the Company's Form 10-K for the year ended December 31, 2013, and other subsequent Securities and Exchange Commission filings.

Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release, the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will", and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information, or otherwise.

Company Contact
CAS Medical Systems, Inc.
Jeffery A. Baird
Chief Financial Officer
(203) 315-6303
ir@casmed.com

Investors
LHA
Don Markley (dmarkley@lhai.com)
(310) 691-7105
Bruce Voss (bvoss@lhai.com)
(310) 691-7100
@LHA_IR_PR

Source:CAS Medical Systems, Inc.